{"id":"https://openalex.org/W4310106654","doi":"https://doi.org/10.1182/blood-2022-167662","title":"Long-Term Analysis of Anti-CD20mab + HDMP for the Treatment of Patients with Chronic Lymphocytic Leukemia","display_name":"Long-Term Analysis of Anti-CD20mab + HDMP for the Treatment of Patients with Chronic Lymphocytic Leukemia","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310106654","doi":"https://doi.org/10.1182/blood-2022-167662"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-167662","doi":"https://doi.org/10.1182/blood-2022-167662","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-167662","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047231615","display_name":"Benjamin Michael Heyman","orcid":"https://orcid.org/0000-0001-6707-0861","observed_orcids":["https://orcid.org/0000-0001-6707-0861"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Heyman","raw_affiliation_strings":["1Moores Cancer Center, University of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moores Cancer Center, University of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075436982","display_name":"Michael Y. Choi","orcid":"https://orcid.org/0000-0002-9107-2186","observed_orcids":["https://orcid.org/0000-0002-9107-2186"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Y. Choi","raw_affiliation_strings":["1Moores Cancer Center, University of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moores Cancer Center, University of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["2Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.21812434,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"12414","last_page":"12415"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.9800000190734863},{"id":"https://openalex.org/keywords/high-dose-methylprednisolone","display_name":"high-dose methylprednisolone","score":0.9459999799728394},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.949999988079071},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":1.0},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.6340000033378601},{"id":"https://openalex.org/keywords/immune-reconstitution","display_name":"immune reconstitution","score":0.7200000286102295},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.4410000145435333},{"id":"https://openalex.org/keywords/relapse-and-progression","display_name":"relapse and progression","score":0.37599998712539673},{"id":"https://openalex.org/keywords/chromosomal-abnormalities","display_name":"chromosomal abnormalities","score":0.4690000116825104}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8397006988525391},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.6824778318405151},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6051661968231201},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5454973578453064},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5227696895599365},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4903531074523926},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45120182633399963},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3826896548271179},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2702493965625763},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.13479503989219666},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.10639607906341553}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-167662","doi":"https://doi.org/10.1182/blood-2022-167662","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-167662","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2977809460","https://openalex.org/W2980502945","https://openalex.org/W2597688858","https://openalex.org/W4248185195","https://openalex.org/W2556182682","https://openalex.org/W2560079614","https://openalex.org/W2589120779","https://openalex.org/W2980656663","https://openalex.org/W2029903885","https://openalex.org/W2561647909"],"abstract_inverted_index":{"Background:":[0],"The":[1,186,218,372,663],"addition":[2,710],"of":[3,44,67,75,85,138,164,173,192,200,213,221,229,242,272,282,356,452,557,570,613,629,634,660,666,673,684,711,727],"an":[4,19,48,275,498,619,714],"anti-CD20":[5,49,620,715],"monoclonal":[6],"antibody":[7],"(mAB)":[8],"to":[9,17,148,301,375,425,433,443,459,468,476,486,550,640,694,713,731,739],"high":[10,627],"dose":[11],"methylprednisolone":[12],"(HDMP)":[13],"has":[14,706],"been":[15,232],"demonstrated":[16],"be":[18,718],"effective,":[20],"non-myelosuppressive":[21],"treatment":[22,377],"(Tx)":[23],"regimen":[24],"for":[25,118,161,365,379,646,704,722],"patients":[26,723],"(Pts)":[27],"with":[28,47,234,238,244,286,289,293,414,447,568,601,615,618,656,671],"chronic":[29],"lymphocytic":[30],"leukemia":[31],"(CLL).":[32],"(Castro":[33],"et":[34],"al.,":[35],"2009)":[36],"We":[37,577],"performed":[38,181],"a":[39,144,159,162,189,245,299,308,316,335,341,353,626,657,719],"single":[40],"institution":[41],"retrospective":[42],"analysis":[43,612],"Pts":[45,62,134,141,168,187,214,230,243,248,273,283,296,305,313,320,327,332,338,387,489,496,558,614,648],"treated":[46,63,233,285,617],"mAB":[50,621,716],"and":[51,57,69,83,104,114,121,125,176,240,267,291,318,343,398,435,478,494,507,542,546,631,676,679],"HDMP":[52,76,623,712],"evaluating":[53],"long-term":[54],"efficacy,":[55],"safety,":[56],"immune":[58],"reconstitution.":[59],"Methods:":[60],"102":[61],"between":[64],"the":[65,250,359,366,380,392,399,701,709],"years":[66,681],"2001":[68],"2015":[70],"were":[71,128,215,284,417,692],"evaluated.":[72],"Tx":[73,201,302,702,720],"consisted":[74],"1gm/m2":[77],"IV":[78,210],"on":[79,100],"days":[80,101],"1,":[81,102],"2,":[82],"3":[84],"each":[86],"cycle.":[87],"Rituximab":[88],"(R)":[89],"was":[90,180,224,369,383,395,402,450,669],"administered":[91,129,156],"as":[92],"either":[93],"375":[94],"mg/m2":[95,98,108],"weekly;":[96],"750":[97,107],"daily":[99,115],"2":[103,225],"3;":[105],"or":[106,735],"weekly":[109],"times":[110,116,158],"during":[111],"cycle":[112,119],"one":[113,344],"three":[117,157,678],"two":[120],"three.":[122],"Obinutuzumab":[123],"(G)":[124],"ofatumumab":[126],"(O)":[127],"per":[130],"FDA":[131],"standard":[132],"dosing.":[133],"received":[135,169,389,559,650],"3-6":[136],"cycles":[137],"Tx.":[139,742],"Some":[140],"who":[142,388,649],"achieved":[143,307,315,334,340],"partial":[145],"response":[146,300,310],"(PR)":[147],"initial":[149],"therapy":[150],"underwent":[151,328],"alemtuzumab":[152],"(Alem)":[153],"consolidation,":[154,391],"10mg,":[155],"week":[160],"total":[163],"eight":[165],"weeks.":[166],"All":[167],"anti-microbial":[170],"prophylaxis":[171],"consisting":[172],"fluconazole,":[174],"bactrim":[175],"acyclovir.":[177],"Response":[178],"assessment":[179],"using":[182],"iwCLL":[183],"criteria.":[184],"Results:":[185],"had":[188,231,298,322,347,653],"median":[190,219,354,360,373,393,400,632,658],"age":[191],"66":[193],"(range;":[194,226],"40-85).":[195],"Rai":[196],"stage":[197],"at":[198,574,583,594,603,689],"time":[199,374],"initiation:":[202],"I":[203],"6%;":[204],"II":[205],"43%;":[206],"III":[207],"17%;":[208],"Stage":[209],"34%.":[211],"63%":[212],"previously":[216],"treated.":[217],"number":[220],"previous":[222],"Txs":[223],"1-5).":[227],"55%":[228],"immunotherapy":[235],"alone,":[236],"67%":[237],"chemoimmunotherapy,":[239],"13%":[241],"BCL2":[246],"inhibitor.":[247],"harbored":[249,274],"following":[251],"cytogenetic":[252],"abnormalities:":[253],"del(13q)":[254],"46%;":[255],"trisomy":[256],"12":[257],"30%;":[258],"del(11q)":[259,263],"22%;":[260,264],"normal":[261,551],"13%;":[262],"del(17p)":[265],"19%;":[266],"complex":[268],"in":[269],"26%.":[270],"58%":[271],"unmutated":[276],"immunoglobulin":[277],"heavy":[278],"chain":[279],"(IGHV).":[280],"84%":[281],"R,":[287],"11%":[288],"G,":[290],"5%":[292,495],"O.":[294],"96":[295],"(94%)":[297],"(OR).":[303],"18":[304],"(18%)":[306],"complete":[309],"(CR);":[311],"78":[312],"(76%)":[314],"PR;":[317,342],"six":[319],"(6%)":[321,346],"stable":[323],"disease":[324,581],"(SD).":[325],"Seventeen":[326],"Alem":[329,350,390,436,479,651],"consolidation.":[330,351],"Twelve":[331],"(71%)":[333],"CR;":[336],"four":[337,680],"(24%)":[339],"patient":[345],"SD":[348],"after":[349,502,682],"With":[352],"follow-up":[355],"114":[357],"months,":[358,397],"progression":[361,593,602,688],"free":[362],"survival":[363],"(PFS)":[364],"entire":[367,381],"cohort":[368,382],"27.1":[370,635],"months.":[371,385,404,576,636,662],"next":[376],"(TTNT)":[378],"30.0":[384],"For":[386],"PFS":[394,416,633,659],"90.1":[396,661],"TTNT":[401,449],"97.8":[403],"(Figure":[405,554],"1A)":[406],"Employing":[407],"cox":[408],"proportional":[409],"hazards":[410],"model,":[411],"factors":[412,566],"associated":[413,446,567],"improved":[415,448],"IGHV":[418,461],"mutated":[419,462],"(HR":[420,428,438,454,463,471,481],"0.38;":[421],"95%":[422,430,440,456,465,473,483],"CI":[423,431,441,457,466,474,484],"0.18":[424,458],"0.79);":[426],"CR":[427,470],"0.17;":[429],"0.05":[432],"0.47);":[434],"consolidation":[437,480,652],"0.21;":[439],"0.09":[442],"0.46).":[444],"Factors":[445],"presence":[451],"del13q":[453],"0.41;":[455],"0.93);":[460],"0.36;":[464],"0.13":[467],"0.92);":[469],"0.12;":[472],"0.03":[475],"0.37);":[477],"0.24;":[482],"0.10":[485],"0.53).":[487],"9%":[488],"developed":[490,497],"infection":[491],"requiring":[492,729],"hospitalization,":[493],"opportunistic":[499],"infection.":[500],"Immediately":[501],"Tx,":[503,728],"serum":[504,544,571,587,674,697],"IgA,":[505],"IgG":[506,521,547,677],"IgM":[508,530],"levels":[509,548,573],"decreased":[510],"(mean":[511],"IgA":[512,545,572,588,591,675,698],"pre-Tx":[513,522,531],"69.4mg/dL":[514],"vs":[515,524,533,598],"post-Tx":[516,525,534],"43.0mg/dL;":[517],"p":[518,527,536,606],"<0.0001;":[519],"mean":[520,529],"738.0mg/dL":[523],"494.3mg/dL;":[526],"<0.001;":[528],"94.8mg/dL":[532],"44.5mg/dL;":[535],"=":[537,607],"0.07).":[538],"At":[539],"approximately":[540],"36-":[541],"48-months":[543],"returned":[549],"levels,":[552],"respectively.":[553],"1B)":[555],"57%":[556],"supplemental":[560],"intravenous":[561],"immunoglobulin,":[562],"thus":[563],"we":[564,624],"investigated":[565],"recovery":[569],"36":[575,584,595,604,690],"found":[578,625,693],"that":[579],"only":[580],"status":[582],"months":[585,596,691],"impacted":[586],"levels.":[589,699],"(Mean":[590],"without":[592,687],"74.7mg/dL":[597],"44.9":[599],"mg/dL":[600],"months;":[605],"0.035).":[608],"Conclusions:":[609],"In":[610],"our":[611],"CLL":[616,705],"+":[622],"OR":[628],"94%":[630],"This":[637],"compares":[638],"favorably":[639],"traditional":[641],"low":[642],"intensity":[643],"chemoimmunotherapy":[644],"approaches":[645],"CLL.":[647],"durable":[654],"remissions,":[655],"overall":[664],"incidence":[665],"infectious":[667],"complications":[668],"manageable,":[670],"normalization":[672],"completion":[683],"therapy.":[685],"Patients":[686],"have":[695],"higher":[696],"While":[700],"landscape":[703],"dramatically":[707],"changed,":[708],"can":[717],"option":[721],"desiring":[724],"short":[725],"course":[726],"bridging":[730],"more":[732],"definite":[733],"therapy,":[734],"debulking":[736],"strategy":[737],"prior":[738],"venetoclax":[740],"based":[741],"Figure":[743],"1View":[744,747],"largeDownload":[745,748],"PPTFigure":[746],"PPT":[749],"Close":[750],"modal":[751]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}